Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411603 | 1.00 | CA1 (0.47) | CA1CA2CA7CA12CA14 | |
| SCHEMBL875372 | 1.00 | CA1 (0.47) | CA1CA2CA7CA12CA14 | |
| SCHEMBL1888284 | 0.84 | CA1 (0.50) | CA1CA2CA7CA12CA14 | |
| SCHEMBL1888283 | 0.84 | CA1 (0.50) | CA1CA2CA7CA12CA14 | |
| SCHEMBL2318522 | 0.84 | CA1 (0.50) | CA1CA2CA7CA12CA14 | |
| SCHEMBL1333292 | 0.82 | CA1 (0.49) | CA1CA2CA7CA12CA14 | |
| Hydrochloric Acid SCHEMBL3606870 | 0.82 | CA1 (0.49) | CA1CA2CA7CA12CA14 | |
| SCHEMBL15947338 | 0.82 | CA1 (0.49) | CA1CA2CA7CA12CA14 | |
| SCHEMBL13715135 | 0.81 | CTSK (0.53) | CA1CA2CA7CA12CA14 | |
| SCHEMBL29395538 | 0.81 | CA12 (0.47) | CA1CA2CA7CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227951-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8546588-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| EP-1730128-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097765-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222139-A1 | Non-peptide gnrh antagonists | FERRING B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| US-5869650-A | POTENTIATE CYTOTOXICITY OF ANTICANCER DRUGS | FOX CHASE CANCER CENTER (US) | 1999-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222139-A1 | Non-peptide gnrh antagonists | GNRHR, BRS3, FSHR | CA1 1502/4885CA2 1509/4885CA7 1389/4885 |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | CA1 2498/4885CA2 1228/4885CA7 2098/4885 |
| US-20080255109-A1 | Non-peptide GnRH antagonists | GNRHR, BRS3, FSHR | CA1 1643/4885CA2 1716/4885CA7 1544/4885 |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CA1 322/4885CA2 249/4885CA7 777/4885 |
| US-20140228416-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CA1 322/4885CA2 249/4885CA7 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.